Delonix Bioworks clears IND for DX-104 vaccine in China & Australia for MenB; Feb 6, 2026.
In Shanghai on February 6, 2026, Delonix Bioworks shared news about their advancements in bacterial vaccine development. The company revealed that their Group B meningococcal vaccine, DX-104, obtained Investigational New Drug (IND) clearance. This signifies a significant step forward for Delonix Bioworks, highlighting their progress in producing next-generation bacterial vaccines.